NCT05647902|Completed
Association of Asprosin in Periodontitis and Acute Coronary Syndrome
Serum Asprosin Concentrations in Patients With Periodontitis and Acute Coronary Syndrome
Loading search results
Serum Asprosin Concentrations in Patients With Periodontitis and Acute Coronary Syndrome
Sponsor study identifier
observational
120
1 country
1
Study Start
January 1, 2022
Actual (reported)Primary Completion
December 30, 2022
Actual (reported)Study Completion
January 1, 2023
Actual (reported)Asprosin, a recently discovered glucogenic adipokine, is mainly synthesized by white adipose tissue and released during fasting. Appetite, glucose metabolism, insulin resistance, cell apoptosis, etc. asprosin is associated with diseases such as diabetes, obesity, polycystic ovary syndrome, and cardiovascular diseases. Periodontal tissue may act as a source of endocrine-like inflammatory mediators (such as TNF-α, IL-6 and IL-1) that are important in periodontal inflammation and can affect glucose and lipid metabolism. Production of TNF-α and IL-6 in adipose tissues strengthens the relationship between cardiovascular diseases and periodontitis. Investigators postulated that asprosin may be a candidate for explaining the triangular relationship between cardiovascular and periodontal disease.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 1, 2023
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 1, 2022
Actual (reported)December 4, 2022
Actual (reported)December 13, 2022
Actual (reported)December 30, 2022
Actual (reported)January 1, 2023
Actual (reported)Asprosin Levels
Determination of asprosin levels by making biochemical analyzes from serum
two weeks
70 systemically healthy patients; 35 healthy gingiva is divided into 2 subgroups, 35 of which are periodontitis. Asprosin levels will be examined biochemically in serum samples taken from patients.
50 patients with myocardial infarction; 25 healthy gingiva is divided into 2 subgroups, 25 of which are periodontitis. Asprosin levels will be examined biochemically in serum samples taken from patients.
Serum samples will be collected from both groups for biochemical analysis.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
The study was carried out on 120 patients, 50 admitted to Atatürk University Medical Faculty Heart Center with SD elevation myocardial infarction and 70 who applied to Atatürk University Faculty of Dentistry. Patients who consent to participate in the study on a randomized basis and comply with the inclusion criteria are divided into periodontitis and healthy groups after the periodontal examination. Body mass index was evaluated
Atatürk University Faculty of Dentistry
Erzurum, 25240, Turkey (Türkiye)
Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, Saha PK, Del Solar M, Zhu B, York B, Sarkar P, Rendon DA, Gaber MW, LeMaire SA, Coselli JS, Milewicz DM, Sutton VR, Butte NF, Moore DD, Chopra AR. Asprosin, a Fasting-Induced Glucogenic Protein Hormone. Cell. 2016 Apr 21;165(3):566-79. doi: 10.1016/j.cell.2016.02.063. Epub 2016 Apr 14.
Yuan M, Li W, Zhu Y, Yu B, Wu J. Asprosin: A Novel Player in Metabolic Diseases. Front Endocrinol (Lausanne). 2020 Feb 19;11:64. doi: 10.3389/fendo.2020.00064. eCollection 2020.
Oğuzhan Birdal, Asist. Prof.
Ataturk University
120 participants (actual enrollment reported by the registry).
First Submitted
December 4, 2022
First Posted
December 13, 2022
Study Start
January 1, 2022
Actual (reported)Connecting Periodontal and Coronary Artery Disease Via the Inflammatory State of the Body
Contact the study team to confirm eligibility.
Primary Completion
December 30, 2022
Actual (reported)Study Completion
January 1, 2023
Actual (reported)Last Updated
July 20, 2023
Record last verified: 2023-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: